Mosaic Family Wealth Partners LLC Purchases 7,228 Shares of Merck & Co., Inc. $MRK

Mosaic Family Wealth Partners LLC raised its position in Merck & Co., Inc. (NYSE:MRK) by 154.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,904 shares of the company’s stock after purchasing an additional 7,228 shares during the quarter. Mosaic Family Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $1,530,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Donaldson Capital Management LLC lifted its stake in Merck & Co., Inc. by 1.7% in the second quarter. Donaldson Capital Management LLC now owns 798,673 shares of the company’s stock worth $102,630,000 after purchasing an additional 13,513 shares during the last quarter. AlTi Global Inc. grew its stake in shares of Merck & Co., Inc. by 2.9% during the second quarter. AlTi Global Inc. now owns 24,188 shares of the company’s stock valued at $3,128,000 after buying an additional 674 shares during the last quarter. HighTower Advisors LLC raised its holdings in shares of Merck & Co., Inc. by 1.2% in the second quarter. HighTower Advisors LLC now owns 3,679,920 shares of the company’s stock worth $472,870,000 after buying an additional 44,516 shares during the period. Advisor OS LLC raised its holdings in shares of Merck & Co., Inc. by 1.7% in the second quarter. Advisor OS LLC now owns 36,859 shares of the company’s stock worth $4,736,000 after buying an additional 613 shares during the period. Finally, TBH Global Asset Management LLC lifted its stake in shares of Merck & Co., Inc. by 15.8% during the 2nd quarter. TBH Global Asset Management LLC now owns 2,984 shares of the company’s stock worth $383,000 after acquiring an additional 408 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the transaction, the executive vice president directly owned 36,613 shares in the company, valued at $4,942,755. This represents a 21.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Richard R. Deluca sold 11,699 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the transaction, the executive vice president directly owned 110,167 shares in the company, valued at $14,501,282.21. This trade represents a 9.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 228,238 shares of company stock valued at $29,977,783 over the last quarter. 0.17% of the stock is owned by company insiders.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. CICC Research started coverage on Merck & Co., Inc. in a report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price objective for the company. Citigroup assumed coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price on the stock. Royal Bank Of Canada downgraded Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and lifted their target price for the stock from $142.00 to $150.00 in a research report on Thursday. BMO Capital Markets upped their price target on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Guggenheim raised their price target on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $144.10.

Merck & Co., Inc. Stock Down 0.1%

Shares of NYSE:MRK opened at $152.43 on Monday. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $154.49. The stock has a market cap of $376.07 billion, a P/E ratio of 121.94, a price-to-earnings-growth ratio of 6.40 and a beta of 0.19. The business’s 50 day moving average is $128.09 and its 200 day moving average is $121.29. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. During the same period in the previous year, the company posted $2.13 EPS. Merck & Co., Inc.’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.